Wockhardt Share Price

Kunal Kamble, sr. technical research analyst at Bonanza, has recommended buying shares of Wockhardt, TFCI, and HBL Engineering today

• Business Standard
• 2 weeks 6 days ago

In the March quarter (Q4FY26), Wockhardt posted net profit year-on-year (Y-o-Y) of 166 crore, as compared to a net loss of 25 crore a year ago

• Business Standard
• 3 weeks 1 day ago

Pharmaceuticals company Wockhardt announced Q4FY26 & FY26 results Q4FY26 Financial Highlights: Total Revenue: In Q4FY26, the company reported total revenue of Rs 965 crore, marking a 30% YoY growth compared to Rs 743 crore in Q4FY25 and an 8.67% QoQ growth from Rs 888 crore in Q3FY26. EBITDA: EBITDA for the quarter stood at Rs 196 crore, representing a 147% YoY growth from Rs 79 crore and a 13.29% QoQ increase from Rs 173 crore in Q3FY26. EBITDA Margin: The company achieved an EBITDA margin of 20.3% in Q4FY26, compared to 10.7% in Q4FY25 and 19.5% in Q3FY26. Profit Before Tax (PBT): The company reported a positive PBT of Rs 189 crore in Q4FY26, a turnaround from a loss of Rs 22 crore in Q4FY25 and a growth of 182% over the Rs 67 crore reported in Q3FY26. Profit After Tax (PAT): PAT stood at Rs 164 crore in Q4FY26, a significant turnaround from a loss of Rs 45 crore in the previous year and a 168.85% increase from Rs 61 crore in Q3FY26. FY26 Financial Highlights: Total Revenue: For FY26, total revenue reached Rs 3,373 crore, an 11% growth compared to Rs 3,033 crore in FY25. EBITDA: Annual EBITDA grew by 51% to Rs 630 crore from Rs 418 crore in the previous year. Profit Before Tax (PBT): The company reported a positive annual PBT of Rs 238 crore for FY26, compared to a loss of Rs 16 crore in FY25. Profit After Tax (PAT): Annual PAT reached Rs 199 crore in FY26, turning around from a loss of Rs 57 crore in FY25. Margins: Annual PAT margin stood at 5.9% for FY26 compared to -1.9% in FY25. Annual EBITDA margin improved to 18.7% from 13.8%. Business Highlights Innovative Portfolio Contribution: The company’s innovative portfolio (including Novel Antibiotics and Biotechnology) contributed 28% of total revenue in Q4FY26 and 23% for the full year FY26. Biotechnology Segment Performance: Biotech operations for the quarter reached Rs 252 crore, recording a growth of 126% vs Q4FY25. For the full year FY26, Biotech operations delivered Rs 697 crore, representing 27% growth. India Branded Business: This segment stood at Rs 112 crore in Q4FY26 (18% growth) and Rs 523 crore for FY26 (15% growth), driven by Diabetic therapy, Novel Chemical Entities (NCE - EMROK), and the Regenerative Derma segment. UK Region: Revenue reached Rs 349 crore in Q4FY26 (+20% YoY) and Rs 1,318 crore for the full year FY26 (+13% YoY). Emerging Markets: This region recorded Rs 320 crore in Q4FY26 (124% growth) and Rs 958 crore for the full year (35% growth), driven primarily by the Biotech Insulin segment and traction in Latin American operations. Irish Region: Revenue stood at Rs 52 crore in Q4FY26 (+12% YoY) and Rs 209 crore for the full year (+16% YoY). Novel Antibiotics Updates: EMA granted Accelerated Assessment for Zaynich®. US FDA NDA and EU EMA MAA reviews are progressing. Miqnaf® Nafithromycin was approved and launched in India with the removal of "supply conditions" by DCGI. Emrok®/Emrok O® grew by 106% vs previous year Q4. India Phase 3 Clinical Trials for Foviscu® were successfully completed. Intellectual Property: One patent was filed and one granted during Q4FY26. The company holds a total of 859 patents with 3,290 cumulative filings to date. Result PDF

• Trendlyne
• 3 weeks 2 days ago